Introduction
Seizures are the most common initial symptom in patients suffering from low-grade glioma. [1] [2] [3] [4] [5] The incidence of seizures highly depends on the histological findings as well as tumor grading. In diffusely infiltrating, low-grade gliomas, oligodendroglial histology strongly correlates with seizure. 1 Tumor localization is another strong predictor for seizures. Patients with temporal, insular and frontal tumors are likely to have seizures, whereas the initial symptoms in patients with occipital and deep-seated lesions are not related to seizures. 1, 4 However, the etiology of tumor-associated seizures is still not fully understood. [2] [3] [4] In about 70-80% of low-grade diffuse gliomas a mutation of the gene encoding the isocitrate-dehydrogenase 1 (IDH1) and 2 (IDH2) is present. 6, 7 IDH1 and IDH2 are NADP + -dependent enzymes located in the cytosol and mitochondria, respectively. Instead of converting isocitrate to a-ketoglutarate, mutant IDH1 reduces a-ketoglutarate to 2-hydroxyglutarate (2HG).
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able to activate NMDA receptors, 9 providing evidence for an epileptogenic potential of 2HG. In L-2-hydroxyglutarate-acidurea (2HGA), a rare, probably autosomal recessive disorder, 2HG levels are elevated in serum, urine and CSF. More than 50% of the mostly pediatric patients present with severe seizures. 10, 11 In this retrospective study we investigate whether IDH1 or IDH2 mutations in diffusely infiltrating, low-grade gliomas with cortical infiltration correspond with seizures as the initial symptom. We excluded WHO grade II oligodendrogliomas from our analysis due to the high frequency of IDH1/2 mutations in these tumors. 12 This distribution would not allow us to set up two groups similar in size to perform statistical analysis. Therefore, we limited our series to grade II astrocytomas. Since many glioma patients without seizures as the initial symptom develop epilepsy during the clinical course, for manifold reasons, 3 we restricted our investigation to seizure as the initial symptom.
Materials and methods
Patients who underwent initial surgery for grade II astrocytoma at the Neurosurgical Department in Rostock and the Charité , Berlin, were selected. The ethic committees of both institutions gave consent for this analysis. All histological findings were re-evaluated according to the established WHO classification of brain tumors 13 by at least two experienced neuropathologists (AvD, CH). Only patients who met the following criteria were included in this study: diagnosis of grade II astrocytoma, available documentation of first tumor symptoms, MRI-proven infiltration of cortex, no anticonvulsant medication prior to the first symptom and availability of either fresh frozen tumor or paraffin-embedded tumor tissue.
Clinical categorization
The clinical files of the patients were evaluated for initial symptoms by an independent neurologist specialized in epileptology who was not involved in treatment of the patients and was blinded to the results of IDH1/2 analysis (UL). The first symptom was designated as either ''non-seizure'' or ''seizure'' and the semiology was classified according to the definitions by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). 14 
Localization
Preoperative MRI scans were reviewed. Infiltration of either the frontal, parietal, occipital, insular or temporal lobe was assigned when the tumor infiltrated more than 1 cm into the cortex of the according lobe. Tumors extending over multiple lobes gave multiple counts.
Determining the mutational status of IDH1/2
The methods and conditions for determining the mutational status of IDH1 and 2 by direct sequencing of PCR products have been described previously. 6, 7 Methods and conditions for detecting the IDH1 R132H mutation by immunohistochemistry (IHC) with mouse monoclonal antibody H09 (Dianova, catalog number DIA H09, Hamburg, Germany) on an automated immunostainer (BenchMark, Ventana Medical Systems, Tuscon, AZ, USA) have been described in detail elsewhere. 15 If no positive staining was observed the tumors were further processed by direct sequencing.
Statistical analysis
The statistical analysis for binary data was performed using the Chi-square test (x 2 ) and multivariate logistic regression (Statistica 9, statsoft, Hamburg, Germany). The metric data were analyzed using the Student's t-test (GraphPad Prism version 5.00, GraphPad Software, San Diego California USA, www.graphpad.com). For all analyses a type I error of a = 5% was defined.
Results
79 patients with grade II astrocytoma were included in the study. The tumors infiltrated the frontal lobe in 45 cases, the temporal lobe in 29, the parietal lobe in 16, the insula in 12 and the occipital lobe in 5. The median age at first operation was 40 years (range 13-72). Seizure was the initial symptom in 57 (72%) patients. The other symptoms were focal neurological deficit in 9 and headache in 11 patients. The tumors were incidental findings in two patients (Table 1) .
Patients with seizure and without seizure as the first symptom had about the same mean age (41.4 vs. 41.7 years, respectively; p = 0.9179, t-test) IDH1/2 mutations were detected in 63 (80%) patients. In 61 patients mutations of IDH1 were identified, resulting in a replacement of arginine to histidine (R132H) in 59, and arginine to cysteine (R132C) in 2 patients at position 132. The mutations of IDH2 resulted in a replacement of arginine to lysine in position 172 (R172K) in 2 patients. All mutations were heterozygous. IDH1 and IDH2 mutations were exclusive (p < 0.0001, x 2 -test). Due to the low number of samples carrying IDH2 mutations we pooled patients with IDH1 and IDH2 mutations. Patients with IDH1/2 mutations were younger than patients with IDH1/2 wild type status (mean 40 vs. 47 years, p = 0.0331, t-test).
Seizure as the initial symptom was associated with IDH1/2
In regard to tumor location, all 12 tumors (100%) located in the insula revealed IDH1/2 mutations, in the frontal lobe, 40 out of 45 (89%), in the temporal lobe 21 of 29 (72%), in the parietal lobe 11 of16 (69%) and in the occipital lobe 3 out of 5 (60%) ( Table 2) . Tumors infiltrating the frontal lobe were associated with an IDH1/2 mutation (p = 0.0202, x 2 -test).
Seizures were most common in tumors involving the temporal lobe (27/29; 83%), followed by the insula (9/12; 74%), the frontal lobe (33/45; 73%) and the parietal lobe (10/17; 59%). Occipital tumors presented with seizures in only 1 in 5 cases (20%) ( Table 2) . Only the occipital lobe revealed a significant association with nonseizure-related initial symptoms (p = 0.0096; x 2 -test). Multivariate logistic regression analysis showed that the IDH1/ 2 mutation appears to be the strongest predictor for seizure as an initial symptom, independent of tumor localization (OR 22.563, p = 0.0019; Table 3 ).
Discussion
We observed an association between seizure as the initial symptom and mutation of IDH 1 or 2, independent of tumor localization, in a series of 79 patients suffering from grade II astrocytoma.
In contrast to our findings, in a series of 49 glioma patients no difference in age and seizure as the first symptom was reported. 16 Since only 7 of these patients had IDH1/2 wild type, these findings are prone to type II error. Investigation of initial symptoms was not in the scope of the study, so there were no inclusion criteria for cortical infiltration or exclusion of deep location. Furthermore, only 37 tumors revealed histology consistent with grade II astrocytoma. Two tumors had oligodendroglial features and in 10 tumors the initial diagnosis was based only on MR findings. Since these features may have an epileptogenic influence, we set up strict exclusion criteria and blinded for classification of initial symptoms.
In our study, 72% of patients with astrocytoma grade II presented with seizures as the initial symptom, which is in line with the 75% reported by van Breemen et al. 2 However, 16% of the patients in our study revealed unspecific complaints such as headache which lead to the tumor diagnosis. A recent study reports low-grade gliomas as incidental findings in 9.6%. 17 Early MRI diagnostics in unspecific complaints was considered to be responsible for this large number. Tumor localization is a known strong predictor for tumorassociated epilepsy. We found the lowest incidence of seizures in patients with occipital and the highest in patients with temporal, frontal and insular tumors. This observation is in line with previous series. 1, 18 Whereas in our study seizures occurred mostly in patients with temporal glioma, IDH1/2 mutations appeared most frequently in tumors of the insula and frontal lobe (Table 1) . This distribution corresponds to the localization pattern of gliomas with combined deletions of 1p and 19q, 19 which are strongly associated with IDH1/2 mutations.
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Interestingly, all tumors involving the insula revealed IDH1/2 mutations. Given the incidence of IDH1/2 mutation in astrocytomas at 73.6%, 7 our series showed statistical significance for the association of IDH1/2 mutation in insular gliomas (p = 0.025).
Many authors have emphasized the unique clinical features of insula gliomas with frequent seizures and favorable, progressionfree and overall survival. 20, 21 As IDH1/2 mutations are associated with prolonged overall survival, 16 the high incidence of IDH1/2 mutations in these tumors may explain these findings. The pathogenesis of tumor-associated seizures is still not fully understood. 3, 4 The strongest evidence for epileptogenesis in lowgrade gliomas comes from microenviromental changes due to tumor metabolism. The report by Olson and co-workers describes a raised level of the excitatory neurotransmitter glutamate in glioma. 22 For cystine uptake, glutamate is exchanged by the cystine-glutamateantiporter xCT. Both glutathione synthesis and xCT expression are increased in low-grade astrocytomas. 23, 24 However, high glutamate levels are associated with malignant gliomas in which seizures are less frequently observed as initial symptoms. 25 In regard to the IDH1/2 mutation-associated changes, further evidence may be the upstream metabolism. Although IDH1 and IDH2 presumably are not part of the tricarboxylic acid cycle (TCA), but IDH3 is, mutation of the former can lead to imbalance, e.g. scarcity of TCA metabolites, by withdrawal due to 2HG accumulation. 8, 26 There are numerous reports on seizures in patients or animal models when the TCA is impaired by inherited disease or toxic interference. [27] [28] [29] In clinical practice, seizures frequently improve by radio-or chemotherapy treatment, even if tumor volume remains unchanged. [30] [31] [32] This gives further evidence that tumor metabolism may cause glioma-induced seizures. The present data bring up an important issue in terms of tumor prevalence, survival and progression analysis. Seizure as a first symptom may precede tumor diagnosis 33 and thus indicate a prolonged survival as well as a longer period without tumor progression. 34 In low-grade astrocytomas, presence of the IDH1/2 mutation has actually been shown to be prognostic when the tumor diagnosis was made on the basis of the first symptom, 16 and has shown no prognostic value when only the date of surgery was considered. 35 On the other hand, seizure as the initial symptom is related to a better overall survival in diffuse gliomas.
36,37
Limitations
In the present study we observed a correlation between a particular genetic mutation and clinical symptoms. However, this is only a correlative study; we do not present additional data that would allow verification of a causal dependency. Furthermore, our patient cohort is too small for further subgroup analysis, e.g. of seizure semiology. Retrospective analysis of initial symptoms based on the patient files appears to be highly problematic. Only few patients were treated in departments specialized at diagnosis of seizures, and we were only able to obtain electroencephalographic data for single patients. Therefore, there was not sufficient data on seizure frequency, response to antiepileptic drugs or changes in semiology, which was mainly due to the decision for immediate surgery as soon as the tumor was diagnosed. Nevertheless, tumor surgery would have allowed cortical encephalography on the tumor, which unfortunately was not performed. This should be carried out in prospective studies.
Conclusion
In grade II astrocytomas, IDH1/2 mutations mostly occur in tumors infiltrating the frontal lobe. Seizure as initial symptom is frequently associated with IDH1/2 mutation. This observation provides evidence that IDH1/2 mutations and consecutive metabolic changes could result in increased epileptogenic activity. 
